Dyadic and Sorrento Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics
Sorrento to obtain exclusive rights in North and South America, Europe, major Asian countries (including Greater China and Japan) and...